Antiphospholipid Syndrome Clinical Research Task Force Report

@article{Erkan2011AntiphospholipidSC,
  title={Antiphospholipid Syndrome Clinical Research Task Force Report},
  author={Doruk Erkan and Rhwm Derksen and R A Levy and Samuel J. Machin and Thomas L. Ortel and S S Pierangeli and Robert A. S. Roubey and Michael D Lockshin},
  journal={Lupus},
  year={2011},
  volume={20},
  pages={219 - 224}
}
The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of six Task Forces developed by the 13th International Congress on Antiphospholipid Antibodies (aPL) organization committee with the purpose of: a) evaluating the limitations of APS clinical research and developing guidelines for researchers to help improve the quality of APS research; and b) prioritizing the ideas for a well-designed multicenter clinical trial and discussing the pragmatics of getting such a trial… Expand
15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report
TLDR
This chapter reviews the rationale for and methodology of the APS new classification criteria development efforts, and develops new evidence-based criteria that will better standardize patients for APS clinical trials and epidemiologic studies. Expand
APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
TLDR
This work aims to find better treatments for antiphospholipid syndrome, which is a leading cause of thrombosis, pregnancy morbidity and other life-altering consequences, and to heighten awareness about this life-threatening, autoimmune condition. Expand
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
TLDR
The scientific contributions of APS ACTION are reviewed to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients. Expand
AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update
TLDR
Details are described related to the organization’s structure, ongoing research efforts, and recent accomplishments and the future directions of APS ACTION are discussed. Expand
Top 10 Clinical Research Developments in Antiphospholipid Syndrome
TLDR
The purpose of this review is to discuss the “top ten” recent clinical developments in APS, including the magnitude of the problem, standardization of aPL tests, predictors of clinical events, diagnostic algorithms, new clinical research collaboration, and potential future treatments, e.g., new anticoagulants and immunosuppressive agents. Expand
Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study.
TLDR
APS patients with elderly onset share a distinct disease profile, with a higher frequency of LA, triple aPL positivity and arterial thrombosis, according to the Elderly-Phospholipid study. Expand
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)
TLDR
This chapter provides a summary of the organization’s structure, ongoing research efforts, and recent accomplishments and discusses future directions. Expand
Antiphospholipid antibody syndrome : Phenotype assessment
Antiphospholipid Syndrome (APS), also known as Hughes Syndrome in honor of the doctor who first described it, is an autoimmune disease characterized by clinical manifestations such as vascularExpand
Risk factors for ischemic antiphospholipid syndrome: A case-control study
TLDR
Patients with primary APS and IS have similar vascular risk factors and lower antibody positivity than those with extracranial thrombosis. Expand
Genetics of Antiphospholipid Syndrome
TLDR
Patients with this syndrome often have systemic lupus erythematosus or related autoimmune diseases, and the syndrome may also occur in the absence of such diseases and it is then known as primary APS. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 12 REFERENCES
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.
TLDR
While traditional risk factors were similar between groups, pregnancy and surgical procedures increased the risk of thrombosis. Expand
Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice
TLDR
Lupus anticoagulants (LA) are generally thought to be more strongly associated with the risk of clinical manifestation of antiphospholipid syndrome (APS) than aCL and anti-β2GPI antibodies. Expand
Risk factors associated with thrombosis in patients with antiphospholipid antibodies.
TLDR
In this hypothesis-generating retrospective study, acquired risk factors were most important in arterial thrombosis, while the presence of factor V(R506Q) and 3' PTG polymorphisms were more important in the development of venous thromBosis. Expand
Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways
TLDR
It is demonstrated that IgGs from patients with diverse clinical manifestations of APS have differential effects upon phosphorylation of NF-κB and p38 MAPK and TF activity that may be mediated by differential activation of TLR4. Expand
The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.
TLDR
In individuals with positive aCL-IgG, there is an association between the number of prothrombotic risk factors and history of thrombosis, and the odds ratio associated with a previous thromBotic event was 1.46 per each additional prothROMboticrisk factor. Expand
Update of the guidelines for lupus anticoagulant detection
TLDR
Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT and the interpretation of the results in general and in particular situations is reported. Expand
Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples
TLDR
A false‐positive LAC diagnosis is not uncommon across specialized centers and patients’ characteristics and a complete antiphospholipid antibody profile may help to identify these individuals. Expand
An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay.
TLDR
The adapted ELISA aCL assay described here was able to discriminate infectious [syphilis, hepatitis C virus, dengue fever, human immunodeficiency virus (HIV) and leprosy] and autoimmune [primary APS and systemic lupus erythematosus (SLE) related APS]. Expand
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
TLDR
The antiphospholipid triangle is studied as a model for the stationary phase of the response of the immune system to various types of drugs. Expand
Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis.
TLDR
In children venous thrombosis appears almost exclusively in association with venous catheters, with an exception of the renal vein thromBosis of the newborn, which has an unknown etiology. Expand
...
1
2
...